CoChat

Microglia produce the amyloidogenic ABri peptide in familial British dementia

Open access

Preprint — published as 10.1007/s00401-024-02820-z · Paper page

The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.

Abstract

Mutations in ITM2B cause familial British, Danish, Chinese and Korean dementias. In familial British dementia (FBD) a mutation in the stop codon of the ITM2B gene (also known as BRI2 ) causes a C-terminal cleavage fragment of the ITM2B/BRI2 protein to be extended by 11 amino acids. This fragment, termed amyloid-Bri (ABri), is highly insoluble and forms extracellular plaques in the brain. ABri plaques are accompanied by tau pathology, neuronal cell death and progressive dementia, with striking parallels to the aetiology and pathogenesis of Alzheimer’s disease. The molecular mechanisms underpinning FBD are ill-defined. Using patient-derived induced pluripotent stem cells, we show that expression of ITM2B/BRI2 is 34-fold higher in microglia than neurons, and 15-fold higher in microglia compared with astrocytes. This cell-specific enrichment is supported by expression data from both mouse and human brain tissue. ITM2B/BRI2 protein levels are higher in iPSC-microglia compared with neurons and astrocytes. Consequently, the ABri peptide was detected in patient iPSC-derived microglial lysates and conditioned media but was undetectable in patient-derived neurons and control microglia. Pathological examination of post-mortem tissue support ABri expression in microglia that are in proximity to pre-amyloid deposits. Finally, gene co-expression analysis supports a role for ITM2B/BRI2 in disease-associated microglial responses. These data demonstrate that microglia are the major contributors to the production of amyloid forming peptides in FBD, potentially acting as instigators of neurodegeneration. Additionally, these data also suggest ITM2B/BRI2 may be part of a microglial response to disease, motivating further investigations of its role in microglial activation. This has implications for our understanding of the role of microglia and the innate immune response in the pathogenesis of FBD and other neurodegenerative dementias including Alzheimer’s disease.

Verification finished with gaps

Some checks didn’t finish. The results below cover the steps that did.

  1. Registry recordVerified
  2. Full textRead the full text
  3. Reference list81 references found
  4. Reference check81 of 81 references checked
  5. StatisticsRecomputed
  6. ClaimsDidn’t finish — the rest of the report still applies.
  7. Cited sourcesDidn’t finish — the rest of the report still applies.
  8. Self-checkChecked
  9. VerificationFindings verified

Overview

CoChat Summary

TL;DR

Using patient-derived iPSCs, this study finds that ITM2B/BRI2 is highly enriched in microglia and that FBD patient-derived microglia produce the amyloidogenic ABri peptide, while patient-derived neurons do not. Post-mortem FBD/FDD tissue and gene co-expression analyses further link ABri/ADan and ITM2B/BRI2 to microglial amyloid responses.

Key findings

  • ITM2B/BRI2 expression was 34-fold higher in iPSC-derived microglia than in iPSC-derived neurons and 15-fold higher than in astrocytes in the abstract (the Results section reports 14-fold for astrocytes); this microglial enrichment was supported by mouse and human brain expression datasets.
  • The 4 kDa ABri peptide was detected in patient iPSC-derived microglial lysates and conditioned media, but was undetectable in patient-derived neurons and control microglia.
  • In post-mortem FBD and FDD hippocampus, ABri/ADan colocalized with microglial markers and Thioflavin-positive amyloid in proximity to pre-amyloid deposits.
  • ITM2B/BRI2 co-expression networks from human AD/MCI microglial scRNA-seq were enriched for ARM/DAM genes including TREM2, TYROBP, C1QA, C1QB, CTSB, CTSS, LAMP2, and HLA genes; ITM2B and TREM2 were upregulated by IFNβ and downregulated by TNFα and LPS, with no significant basal inflammatory differences between control and FBD microglia.

Methods

  • Patient-derived iPSCs from two FBD donors with the c.799 T>A mutation and control lines were differentiated into cortical neurons, astrocytes, and microglia-like cells; analyses included qPCR, Western blotting, immunocytochemistry, and siRNA knockdown of ITM2B/BRI2.
  • Post-mortem hippocampal tissue from one FBD case and one FDD case was examined by immunohistochemistry, in situ hybridisation, and Thioflavin staining.
  • Gene co-expression analysis used HumanBase, GeneFriends, and COXPRESdb, plus scRNA-seq microglia from AD and MCI dorsolateral prefrontal cortex with CoExpNets/WGCNA; microglia were treated with IFNβ, TNFα, or LPS.

Limitations

  • The paper states that FBD is extremely rare, limiting the number of patient-derived iPSC lines and access to brain tissue; future work will use genome editing and expand to other ITM2B-linked dementias.
  • The paper states that gene co-expression network analysis was performed on Alzheimer’s disease brain datasets rather than FBD tissue, and that iPSC neurons have a foetal-like transcriptome, so increased neuronal ITM2B expression at extended time points cannot be excluded.
  • The paper states that other cell types, such as endothelial cells and oligodendrocytes, cannot be discounted as contributors to ABri production, especially given the high angiopathy burden; evident limitations include immunohistochemistry from one FBD and one FDD donor, non-quantitative in situ hybridisation, microglial batch variability, and an uncertain 25 kDa band in human brain samples.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1101/2023.06.27.546552

Cites

80 of 81 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 ABri is produced by iPSC-derived microglia. A Immunocytochemistry of iPSCs (upper panels), iPSC-derived neurons (middle panels) and iPSC-derived microglia (lower panels). SSEA4 and OCT4 are pluripotency markers, scale bar 200 μm. TUJ1 is a pan-neuronal marker and TBR1 labels deep layer cortical neurons, scale bar 200 μm. IBA1 labels microglia-like cells, scale bar 50 μm. B qPCR analysis of ITM2B/BRI2 and FURIN expression in control iPSC-derived cortical neurons, astrocytes and microglia. Neuronal cDNA represents 5 independent inductions with 2 independent control iPSC lines, astrocytic cDNA was generated from 5 independent inductions of two independent control iPSC lines and microglial cDNA was generated from 6 harvests from 4 inductions and represents two independent control iPSC lines. Significant differences are abolished by the outlier at two standard deviations above the mean. C Representation of antibodies used in this figure (produced in biorender). D Western blotting of iPSC-derived neurons, iPSC-derived astrocytes and iPSC-derived microglia. ITM2B/BRI2 knockdown via siRNA depicts antibody specificity for bands at around 30 kDa and 12 kDa. TUJ1, SOX9 and TREM2 are markers for neurons, astrocytes and microglia respectively. Samples represent two independent control lines for each cell type. Microglial samples from independent batches are separated by a dotted line. E Quantification of specific bands (30 kDa and 12 kDa) from 3 independent neuronal, astrocyte and microglia inductions of at least two control lines in each cell type. F Western blotting of iPSC neurons, iPSC microglia and post-mortem brain tissue for ITM2B/BRI2 as well as neuronal TUJ1, microglial TREM2 and loading control (Actin). G Quantification of Western blotting of ITM2B/BRI2 in control and patient-derived microglia from four harvests from three independent batches of microglia. H–J) Western blotting for ABri in iPSC-derived microglia lysates and brain tissue showed a band of 4 kDa. J) Western blotting for ABri in iPSC-derived microglial conditioned media, with secreted APP (sAPP) and GRN as neuronal and microglial loading controls respectively. White arrowheads show full length ITM2B/BRI2, grey arrowheads show cleaved fragments of ITM2B/BRI2 and asterisks show potential unspecific bands. Comparisons represent two tailed t-tests where * = p < 0.05, ** = p < 0.01, *** = p < 0.001
Fig. 1 ABri is produced by iPSC-derived microglia. A Immunocytochemistry of iPSCs (upper panels), iPSC-derived neurons (middle panels) and iPSC-derived microglia (lower panels). SSEA4 and OCT4 are pluripotency markers, scale bar 200 μm. TUJ1 is a pan-neuronal marker and TBR1 labels deep layer cortical neurons, scale bar 200 μm. IBA1 labels microglia-like cells, scale bar 50 μm. B qPCR analysis of ITM2B/BRI2 and FURIN expression in control iPSC-derived cortical neurons, astrocytes and microglia. Neuronal cDNA represents 5 independent inductions with 2 independent control iPSC lines, astrocytic cDNA was generated from 5 independent inductions of two independent control iPSC lines and microglial cDNA was generated from 6 harvests from 4 inductions and represents two independent control iPSC lines. Significant differences are abolished by the outlier at two standard deviations above the mean. C Representation of antibodies used in this figure (produced in biorender). D Western blotting of iPSC-derived neurons, iPSC-derived astrocytes and iPSC-derived microglia. ITM2B/BRI2 knockdown via siRNA depicts antibody specificity for bands at around 30 kDa and 12 kDa. TUJ1, SOX9 and TREM2 are markers for neurons, astrocytes and microglia respectively. Samples represent two independent control lines for each cell type. Microglial samples from independent batches are separated by a dotted line. E Quantification of specific bands (30 kDa and 12 kDa) from 3 independent neuronal, astrocyte and microglia inductions of at least two control lines in each cell type. F Western blotting of iPSC neurons, iPSC microglia and post-mortem brain tissue for ITM2B/BRI2 as well as neuronal TUJ1, microglial TREM2 and loading control (Actin). G Quantification of Western blotting of ITM2B/BRI2 in control and patient-derived microglia from four harvests from three independent batches of microglia. H–J) Western blotting for ABri in iPSC-derived microglia lysates and brain tissue showed a band of 4 kDa. J) Western blotting for ABri in iPSC-derived microglial conditioned media, with secreted APP (sAPP) and GRN as neuronal and microglial loading controls respectively. White arrowheads show full length ITM2B/BRI2, grey arrowheads show cleaved fragments of ITM2B/BRI2 and asterisks show potential unspecific bands. Comparisons represent two tailed t-tests where * = p < 0.05, ** = p < 0.01, *** = p < 0.001CC BY · PubMed Central
Fig. 2 Immunohistochemical staining in FBD for ABri, Thioflavin and microglial markers. ABri pathology is observed in the hippocampus (A) in the form of extracellular amyloid and preamyloid deposits. ABri is also found within parenchymal and leptomeningeal blood vessels as cerebral amyloid angiopathy. ABri pre-amyloid plaques are shown at higher magnification in (B). The preamyloid deposits contained cells resembling microglia morphology (C, arrows). The bar represents 500 µm in (A) and 50 µm in (B) and 25 µm in (C). ABri immunohistochemistry (red, row D and E) combined with Thioflavin staining highlights the presence of ABri in cells resembling microglia. Microglial antibodies were used to determine the Thioflavin positive structures identified in the cells (rows F and G). The bar represents 100 µm in row (D) and 20 µm in row (E) and 10 µm rows in (F) and (G). Data are from one donor
Fig. 2 Immunohistochemical staining in FBD for ABri, Thioflavin and microglial markers. ABri pathology is observed in the hippocampus (A) in the form of extracellular amyloid and preamyloid deposits. ABri is also found within parenchymal and leptomeningeal blood vessels as cerebral amyloid angiopathy. ABri pre-amyloid plaques are shown at higher magnification in (B). The preamyloid deposits contained cells resembling microglia morphology (C, arrows). The bar represents 500 µm in (A) and 50 µm in (B) and 25 µm in (C). ABri immunohistochemistry (red, row D and E) combined with Thioflavin staining highlights the presence of ABri in cells resembling microglia. Microglial antibodies were used to determine the Thioflavin positive structures identified in the cells (rows F and G). The bar represents 100 µm in row (D) and 20 µm in row (E) and 10 µm rows in (F) and (G). Data are from one donorCC BY · PubMed Central
Fig. 3 Immunohistochemical staining in FDD for ADan, thioflavin and microglial markers. ADan pathology was observed in the hippocampus (A) in the form of extracellular pre-amyloid deposits and cerebral amyloid angiopathy. At higher magnification we observed the preamyloid deposits (B). Structures resembling microglia are also found to be highlighted with the ADan immunohistochemical preparations in the pre-amyloid deposits (C, arrows). The bar represents 500 µm in (A) and 50 µm in (B) and 25 µm in (C). ADan immunohistochemistry (red, row D and E) combined with Thioflavin staining (green) highlights the presence of ADan in cells resembling microglia. Microglial antibodies were used to determine the Thioflavin positive structures identified in the cells (rows F and G, arrows). The bar represents 100 µm in row (D) and 20 µm in row (E) and 10 µm rows in (F) and (G). Data is from one donor
Fig. 3 Immunohistochemical staining in FDD for ADan, thioflavin and microglial markers. ADan pathology was observed in the hippocampus (A) in the form of extracellular pre-amyloid deposits and cerebral amyloid angiopathy. At higher magnification we observed the preamyloid deposits (B). Structures resembling microglia are also found to be highlighted with the ADan immunohistochemical preparations in the pre-amyloid deposits (C, arrows). The bar represents 500 µm in (A) and 50 µm in (B) and 25 µm in (C). ADan immunohistochemistry (red, row D and E) combined with Thioflavin staining (green) highlights the presence of ADan in cells resembling microglia. Microglial antibodies were used to determine the Thioflavin positive structures identified in the cells (rows F and G, arrows). The bar represents 100 µm in row (D) and 20 µm in row (E) and 10 µm rows in (F) and (G). Data is from one donorCC BY · PubMed Central
Fig. 4 ITM2B is coexpressed with ARM network genes and responds to inflammatory cues in a similar manner to TREM2. A Genetic network plot of a module containing ITM2B detected in microglial cells isolated from human Alzheimer’s disease patients and individuals with MCI analysed by scRNA-seq [44] demonstrating ITM2B is coexpressed with ARM network genes in microglia isolated from human individuals showing neurodegeneration (and collectively varying between AD and MCI donors). Genes varying in response to AD with the highest connectivity to ITM2B from the co-expression network were plotted based on ranking the connectivity matrix of the expression data. This module contains genes associated with the DAM/ARM state (the full network and the strength of each interaction is given in Supplementary Table 1). Genes most strongly co-expressed with ITM2B include genes known to be associated with neurodegeneration including LAPTM5, HLA genes, CTSB, CTSS, GRN, TREM2 and TYROBP. ITM2B is highlighted with a yellow oval. B, C qPCR expression analyses of ITM2B and TREM2 in response to a 24 h treatment with IFNβ and TNFα. Data represent n = 4 for untreated and IFNβ and n = 3 for TNFα, each from 2 independent batches of microglia and for two control iPSC lines and two FBD lines. Data separated by genotype is presented in Fig S8B. Paired t-tests were performed for each treatment relative to untreated samples, * = p < 0.05, ** = p < 0.01. D–I qPCR analyses of genes associated with microglial state changes under basal conditions. Data represent 6 ≤ n ≤ 11 from 3 independent batches of microglia
Fig. 4 ITM2B is coexpressed with ARM network genes and responds to inflammatory cues in a similar manner to TREM2. A Genetic network plot of a module containing ITM2B detected in microglial cells isolated from human Alzheimer’s disease patients and individuals with MCI analysed by scRNA-seq [44] demonstrating ITM2B is coexpressed with ARM network genes in microglia isolated from human individuals showing neurodegeneration (and collectively varying between AD and MCI donors). Genes varying in response to AD with the highest connectivity to ITM2B from the co-expression network were plotted based on ranking the connectivity matrix of the expression data. This module contains genes associated with the DAM/ARM state (the full network and the strength of each interaction is given in Supplementary Table 1). Genes most strongly co-expressed with ITM2B include genes known to be associated with neurodegeneration including LAPTM5, HLA genes, CTSB, CTSS, GRN, TREM2 and TYROBP. ITM2B is highlighted with a yellow oval. B, C qPCR expression analyses of ITM2B and TREM2 in response to a 24 h treatment with IFNβ and TNFα. Data represent n = 4 for untreated and IFNβ and n = 3 for TNFα, each from 2 independent batches of microglia and for two control iPSC lines and two FBD lines. Data separated by genotype is presented in Fig S8B. Paired t-tests were performed for each treatment relative to untreated samples, * = p < 0.05, ** = p < 0.01. D–I qPCR analyses of genes associated with microglial state changes under basal conditions. Data represent 6 ≤ n ≤ 11 from 3 independent batches of microgliaCC BY · PubMed Central

Verification

Claims the paper makes

This check didn’t finish.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Research works printed but not linked: 1

  1. 10.1523/jneurosci.1860-14.2014 · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Arber, C., Casey, J. M., Crawford, S., Rambarack, N., Yaman, U., Wiethoff, S., Augustin, E., Piers, T. M., Rostagno, A., Ghiso, J., Lewis, P. A., Revesz, T., Hardy, J., Pocock, J. M., Houlden, H., Schott, J. M., Salih, D. A., Lashley, T., & Wray, S.
Affiliations
  • UCL Queen Square Institute of Neurology (GB)
  • University College London (GB)
  • University of Münster (DE)
  • New York University (US)
  • Royal Veterinary College (GB)
Corresponding author
  • Lashley, Tammaryn
  • Wray, Selina
Venue
Acta Neuropathologica
Publisher
openRxiv
Published
2023-06-28
Volume
148
Issue
1
Pages
65-65
ISSN
0001-6322 (ISSN-L)
OpenAlex
W4404421557
Cited by
9
References
79
Citations by year
2026: 4 · 2025: 4 · 2023: 1
FWCI
0.95
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion)
  • PubMed (submittedVersion)
Funders
  • European Federation of Pharmaceutical Industries and Associations
  • Alzheimer's Society (AS‐JF‐18‐008)
  • National Institute for Health and Care Research
  • University College London
  • European Commission (HORIZON2020, 115976)
  • Alzheimer’s Research UK (ARUKSRF2016B-2)
  • University College London Hospitals NHS Foundation Trust
  • Innovative Medicines Initiative (115976)
  • National Institutes of Health (RF1AG059695)
  • Medical Research Council (MR/M02492X/1)
  • Engineering and Physical Sciences Research Council (EP/N509577/1)
  • UCLH Biomedical Research Centre
  • National Institute on Aging (RF1 AG059695)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
familial British dementia, ITM2B, BRI2, microglia, amyloid plaques, induced pluripotent stem cell-derived microglia, tau pathology, neurodegeneration, microglial activation, Alzheimer's disease, innate immune response, gene co-expression
MeSH terms
Animals, Brain, Dementia, Humans, Neurons, Amyloid beta-Peptides, Microglia, Adaptor Proteins, Signal Transducing, Mice, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.